Drugs discovered today can realistically cost upwards of 900 million dollars and around 12 years of development to reach a market. CRO’s have been increasingly used by larger pharma to outsource their clinical research, allowing big pharma to shut down in-house R&D, in practice saving money.
There have been some issues however with the outsourcing of trials to CROs, including serious relationship break down with negative attitudes, failure to communicate between to the partners and some claiming CROs do not ‘get in the spirit’ of the research following only the letter of the contract.
SMi’s 4th annual Managing Partnerships with CROs held on the 3rd & 4th October, London will look to focus on 5 main areas: Optimising interaction between sponsors and CROs, Developing and executing strategic partnership models, Partner selection, Risk management and improving communication. It will provide delegates with a comprehensive overview and analysis of outsourcing in the pharmaceutical sector, offering the unique opportunity to hear from representatives from Pharma, CRO and Academia with an emphasis creating strong and successful partnerships between all parties.
Companies already registered include:
- Novartis Vaccines
- Eli Lilly
- Bayer HealthCare Pharmaceuticals
- Teva Pharmaceuticals Ltd.
- Biogen Idec Ltd
- Booz and Company
- Quintiles Ltd
- PA Consulting Group
- NIHR Clinical Research Network Coordinating Centre
Quote MNT and save £100
For more information visit http://www.smi-online.co.uk/pharmaoutsourcingevent64.asp alternatively contact Fateja Begum on +44 0 207 827 6184 or email [email protected]
SMi Group Ltd